DK2879691T3 - Fremgangsmåder og sammensætninger til inaktivering af kappebærende vira - Google Patents

Fremgangsmåder og sammensætninger til inaktivering af kappebærende vira Download PDF

Info

Publication number
DK2879691T3
DK2879691T3 DK13750235.7T DK13750235T DK2879691T3 DK 2879691 T3 DK2879691 T3 DK 2879691T3 DK 13750235 T DK13750235 T DK 13750235T DK 2879691 T3 DK2879691 T3 DK 2879691T3
Authority
DK
Denmark
Prior art keywords
disabling
creative
wear
compositions
methods
Prior art date
Application number
DK13750235.7T
Other languages
English (en)
Inventor
Lynn Edward Conley
Yinying Tao
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Application granted granted Critical
Publication of DK2879691T3 publication Critical patent/DK2879691T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761Methods of inactivation or attenuation
    • C12N2710/16763Methods of inactivation or attenuation by chemical treatment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/13011Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061Methods of inactivation or attenuation
    • C12N2740/13063Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK13750235.7T 2012-08-06 2013-08-06 Fremgangsmåder og sammensætninger til inaktivering af kappebærende vira DK2879691T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261680039P 2012-08-06 2012-08-06
PCT/US2013/053781 WO2014025771A2 (en) 2012-08-06 2013-08-06 Methods and compositions for inactivating enveloped viruses

Publications (1)

Publication Number Publication Date
DK2879691T3 true DK2879691T3 (da) 2019-06-11

Family

ID=48986268

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13750235.7T DK2879691T3 (da) 2012-08-06 2013-08-06 Fremgangsmåder og sammensætninger til inaktivering af kappebærende vira

Country Status (5)

Country Link
US (2) US10188732B2 (da)
EP (2) EP2879691B1 (da)
JP (2) JP6465800B2 (da)
DK (1) DK2879691T3 (da)
WO (1) WO2014025771A2 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2879691B1 (en) 2012-08-06 2019-03-27 Biogen MA Inc. Methods for inactivating enveloped viruses
EP3696267A1 (en) * 2014-09-17 2020-08-19 Helixbind Inc. Methods for lysing eukaryotic cells
CN108700519B (zh) * 2016-02-24 2021-07-30 生物辐射实验室股份有限公司 用于荧光检测的方法和组合物
BR112019000872A2 (pt) 2016-08-16 2019-04-30 Regeneron Pharmaceuticals, Inc. métodos para quantificar anticorpos individuais de uma mistura
CA3039788A1 (en) 2016-10-25 2018-05-03 Regeneron Pharmaceuticals, Inc. Methods and systems for chromatography data analysis
JP7317005B2 (ja) 2017-09-18 2023-07-28 バイエル・ヘルスケア・エルエルシー N-メチルグルカミドとその誘導体を使用したウイルスの不活化方法
WO2019060062A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals Inc. METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM
TW202005694A (zh) 2018-07-02 2020-02-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
US20220002679A1 (en) 2018-11-15 2022-01-06 Bayer Healthcare Llc Viral Inactivation Methods for Continuous Manufacturing of Antibodies
US20220106573A1 (en) * 2019-03-19 2022-04-07 Amgen Inc. Alternate detergents for viral inactivation
CN110424030B (zh) * 2019-08-30 2020-06-30 广州三孚新材料科技股份有限公司 无氰碱性电镀铜液及其制备和在挠性印刷线路板中的应用
US11643641B2 (en) 2021-03-04 2023-05-09 Malireddy S. Reddy Prevention of viral transmission by naked genetic material
EP4359010A1 (en) 2021-06-21 2024-05-01 uniQure biopharma B.V. Improved lysis procedures
WO2024115344A1 (en) 2022-11-29 2024-06-06 Merck Patent Gmbh Method for inactivating enveloped viruses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE242716C (da)
DD242716A3 (de) * 1981-08-28 1987-02-11 Adw Der Ddr Inst F Chem Techno Verfahren zur herstellung von gereinigten antigenen bzw. biopraeparaten
DE3704550A1 (de) * 1987-02-13 1988-08-25 Behringwerke Ag Verfahren zur inaktivierung huellhaltiger viren in mittels einer zelle in vitro hergestellten protein-praeparationen
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5314917A (en) 1991-03-22 1994-05-24 E. B. Michaels Research Associates, Inc. Method for inactivating enveloped viruses and sperm
FR2805163A1 (fr) * 2000-02-21 2001-08-24 Pf Medicament Utilisation d'un detergent de type zwittergent pour la preparation d'une composition pharmaceutique destinee a etre administree par voie nasale
US6635679B2 (en) * 2001-05-14 2003-10-21 Akzo Nobel N.V. Methods and compositions for inactivating viruses
CA2551896A1 (en) * 2003-12-30 2005-07-21 Wyeth Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
NZ568211A (en) * 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
EP1970440A1 (en) * 2007-03-06 2008-09-17 Qiagen GmbH Polymerase stabilization by ionic detergents
NZ611994A (en) * 2010-12-15 2015-04-24 Baxter Healthcare Sa Viral inactivation using improved solvent-detergent method
GB201216121D0 (en) * 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
EP2879691B1 (en) 2012-08-06 2019-03-27 Biogen MA Inc. Methods for inactivating enveloped viruses

Also Published As

Publication number Publication date
US10188732B2 (en) 2019-01-29
EP2879691A2 (en) 2015-06-10
US20190175738A1 (en) 2019-06-13
WO2014025771A3 (en) 2014-04-17
EP3456352A1 (en) 2019-03-20
JP2015525572A (ja) 2015-09-07
EP2879691B1 (en) 2019-03-27
US20150306223A1 (en) 2015-10-29
JP2019037234A (ja) 2019-03-14
JP6833788B2 (ja) 2021-02-24
JP6465800B2 (ja) 2019-02-06
WO2014025771A2 (en) 2014-02-13
US10702603B2 (en) 2020-07-07

Similar Documents

Publication Publication Date Title
DK2879691T3 (da) Fremgangsmåder og sammensætninger til inaktivering af kappebærende vira
DK2890780T3 (da) Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand
DK2773635T3 (da) Forbindelser og sammensætninger til modulering af EGFR-aktivitet
DK3363901T3 (da) Sammensætninger og fremgangsmåder til præcis identificering af mutationer
DK2812452T3 (da) Fremgangsmåder og sammensætninger til screening og behandling af udviklingsforstyrrelser
DK2906696T3 (da) Fremgangsmåder til modulering af c9orf72-ekspression
DK2838917T3 (da) Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
DK2914741T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til forbedring af PCR-specificitet
DK2911506T3 (da) Driftreducerende sammensætninger
UA26820S (uk) Телефон головний
BR112013022112A2 (pt) composição
DK3241547T3 (da) Lyofiliseret præparat af botulinumtoksin
BR112013022102A2 (pt) composição
DK2766483T3 (da) Fremgangsmåder og sammensætninger til screening for og behandling af udviklingsforstyrrelser
DK2686017T3 (da) Oftalmisk sammensætning
DK2665486T3 (da) Sammensætninger til modulering af gamma-c-cytokin-aktivitet
BR112014004395A2 (pt) composição
BR112014032798A2 (pt) composição
DK4011364T3 (da) Fremgangsmåder og sammensætninger til behandling af ADD (Attention Deficit Disorder)
DK2855500T3 (da) Fremgangsmåder og sammensætninger til modulering af apolipoprotein (A)-ekspression
DK2922955T3 (da) Sammensætninger og fremgangsmåder til modulering af FGFR3-ekspression
DK2830654T3 (da) Metoder og sammensætninger til behandling af inflammation
BR112013033808A2 (pt) composição
ES2721400T8 (es) Composición de Diclofenaco
DK2849798T3 (da) Oligonukleotid-chelatkompleks-polypeptidsammensætninger og fremgangsmåder